Show simple item record

dc.contributor.authorAlireza Nikoofar
dc.contributor.authorZohreh Hoseinpour
dc.contributor.authorSeied Rabi Mahdavi
dc.contributor.authorHadi Hasanzadeh
dc.contributor.authorMostafa Rezaei Tavirani
dc.date.accessioned2017-09-18T10:48:46Z
dc.date.available2017-09-18T10:48:46Z
dc.date.issued2015-05-22
dc.identifier.urihttp://dsp.sbmu.ac.ir/xmlui/handle/123456789/67082
dc.description.abstract© 2015, Iranian Journal of Cancer Prevention. Background: The high-dose-rate (HDR) brachytherapy might be an effective tool for palliation of dysphagia. Because of some concerns about adverse effects due to absorbed radiation dose, it is important to estimate absorbed dose in risky organs during this treatment. Objectives: This study aimed to measure the absorbed dose in the parotid, thyroid, and submandibular gland, eye, trachea, spinal cord, and manubrium of sternum in brachytherapy in an anthropomorphic phantom. Materials and Methods: To measure radiation dose, eye, parotid, thyroid, and submandibular gland, spine, and sternum, an anthropomorphic phantom was considered with applicators to set thermoluminescence dosimeters (TLDs). A specific target volume of about 23 cm < sup > 3 < /sup > in the upper thoracic esophagus was considered as target, and phantom planned computed tomography (CT) for HDR brachytherapy, then with a micro-Selectron HDR ( < sup > 192 < /sup > Ir) remote after-loading unit. Results: Absorbed doses were measured with calibrated TLDs and were expressed in centi-Gray (cGy). In regions far from target (≥ 16 cm) such as submandibular, parotid and thyroid glands, mean measured dose ranged from 1.65 to 5.5 cGy. In closer regions (≤ 16 cm), the absorbed dose might be as high as 113 cGy. Conclusions: Our study showed similar depth and surface doses; in closer regions, the surface and depth doses differed significantly due to the role of primary radiation that had imposed a high-dose gradient and difference between the plan and measurement, which was more severe because of simplifications in tissue inhomogeneity, considered in TPS relative to phantom.
dc.sourceIranian Journal of Cancer Prevention
dc.subjectBrachytherapy
dc.subjectEsophageal cancer
dc.subjectPhantom
dc.titleHigh-dose-rate 192Ir brachytherapy dose verification: A phantom study
dc.journal.volume8
dc.journal.issue3
dc.identifier.doi10.17795/ijcp2330
dc.journal.pages
dc.contributor.authorid14120231200
dc.contributor.authorid56871153300
dc.contributor.authorid6603806138
dc.contributor.authorid35746224300
dc.contributor.authorid55891568600
dc.contributor.citation14120231200|60024852|Alireza Nikoofar
dc.contributor.citation56871153300|60024530|Zohreh Hoseinpour
dc.contributor.citation6603806138|60024852|Seied Rabi Mahdavi
dc.contributor.citation35746224300|60024530|Hadi Hasanzadeh
dc.contributor.citation55891568600|60018934|Mostafa Rezaei Tavirani
dc.contributor.affiliationid60024852
dc.contributor.affiliationid60024530
dc.contributor.affiliationid60024852
dc.contributor.affiliationid60024530
dc.contributor.affiliationid60018934


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record